Replies to post #597927 on NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

Maverick0408,

They are applying for the toughest cancer indications to gain any traction in, they will be approved for those indications and word will quickly get out that this is a SAFE platform treatment that works especially well in aggressive mesenchymal cancers that most solid tumor cancers transition to at progression. I dare you to stand in front of the mob demanding this be made available for all solid tumors and tell them they will just have to wait!; ).
Stuff that works off label gets used off label. Simple as that and with evidence in the books already that this works in Ovarian cancer and others and that Direct was tested in multiple cancers with survivors still around from various indications and that Direct is just a less matured version of L you might want to step out of the way... that is unless you are an experienced runner with the bulls in Spain and on ihub ; ). Best wishes.

[Roman516]

The real truth of NWBO with regards to nGBM, rGBM, and multiple solid tumors.

Per your comments
"They are not applying for all solid tumors, so stop with this BS! They are only applying for GBM."

https://investorshub.advfn.com/secure/post_reply.aspx?message_id=172047644

About Northwest Biotherapeutics

"Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company's lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an "orphan disease." This Phase III trial has been completed, and the results have been presented in scientific meetings and published in JAMA Oncology. The Company has also developed DCVax®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and, as resources permit, plans to pursue Phase II trials. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania."

There is no BS here as NWBO in conjunction with Dr. Linda Liau plus many other individuals are all working on many other solid tumors and that is a FACT, IMPO.
NWBO will be submitting applications for many solid tumors and that is a FACT as well.

[biosectinvestor]

One approval is all that is actually required now to rapidly open the door not just to expanding the label but also getting insurance and Medicare coverage with real world data. The whole point of the 21st Century Cures act is to make access to real breakthrough cancer drugs as rapid as possible.